About: Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
Creator	Ichihara, Atsuhiro Tanaka, • Kario, Kazuomi Arima, Hisatomi Asayama, • Hoshide, • Itoh, • Kishi, Takuya Mogi, Masaki Nishiyama, Akira Ohishi, Mitsuru Ohkubo, • Shibata, Shigeru Tamura, Kouichi Toshihiko, • Yamamoto, Eiichiro Yamamoto, •
Source	Medline; PMC
abstract	Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than seven million people worldwide, contributing to 0.4 million deaths as of June 2020. The fact that the virus uses angiotensin-converting enzyme (ACE)-2 as the cell entry receptor and that hypertension as well as cardiovascular disorders frequently coexist with COVID-19 have generated considerable discussion on the management of patients with hypertension. In addition, the COVID-19 pandemic necessitates the development of and adaptation to a “New Normal” lifestyle, which will have a profound impact not only on communicable diseases but also on noncommunicable diseases, including hypertension. Summarizing what is known and what requires further investigation in this field may help to address the challenges we face. In the present review, we critically evaluate the existing evidence for the epidemiological association between COVID-19 and hypertension. We also summarize the current knowledge regarding the pathophysiology of SARS-CoV-2 infection with an emphasis on ACE2, the cardiovascular system, and the kidney. Finally, we review evidence on the use of antihypertensive medication, namely, ACE inhibitors and angiotensin receptor blockers, in patients with COVID-19.
has issue date	2020-07-31(xsd:dateTime)
bibo:doi	10.1038/s41440-020-0515-0
bibo:pmid	32737423
has license	no-cc
sha1sum (hex)	77defc0635d3c1e3c6c87de01fa868afc5cedb7d
schema:url	https://doi.org/10.1038/s41440-020-0515-0
resource representing a document's title	Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19
has PubMed Central identifier	PMC7393334
has PubMed identifier	32737423
schema:publication	Hypertens Res
resource representing a document's body	covid:77defc0635d3c1e3c6c87de01fa868afc5cedb7d#body_text
is schema:about of	named entity 'COVID-19' named entity 'existing' named entity 'patients' named entity 'patients' named entity 'hypertension' named entity 'COVID-19' named entity 'Hypertension' named entity 'KNOWLEDGE' named entity 'MORE THAN' named entity 'JUNE' named entity 'CARDIOVASCULAR DISORDERS' named entity 'ADDRESS' named entity 'WHAT' named entity 'blockers' named entity 'SARS-CoV-2' named entity 'impact' named entity 'COVID-19' named entity 'cardiovascular disorders' named entity 'face' named entity 'virus' named entity 'COVID' named entity 'COVID' named entity 'infection' named entity 'hypertension' named entity 'virus' named entity 'ACE' named entity 'Hypertension' named entity 'SARS-CoV-2' named entity 'CVDs' named entity 'beta-blockers' named entity 'cytokine' named entity 'diabetes' named entity 'Hypertension' named entity 'clinical outcome' named entity 'COVID' named entity 'hypertension' named entity 'March 2020' named entity 'RBD' named entity 'medical practice' named entity 'hypertension' named entity 'COVID' named entity 'endothelial cells' named entity 'SARS' named entity 'SARS' named entity 'physical activity' named entity 'ARBs' named entity 'cell-surface' named entity 'SARS-CoV-2' named entity 'malignant' named entity 'infection' named entity 'influenza vaccination' named entity 'confounding factors' named entity 'losartan' named entity 'thrombotic complications' named entity 'comorbidities' named entity 'New York' named entity 'ACE2' named entity 'inflammatory factors' named entity 'peptides' named entity 'podocytes' named entity 'chronic kidney disease' named entity 'kidney diseases' named entity 'innate immune response' named entity 'ACE2' named entity 'COVID-19 pandemic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software